Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia
Tóm tắt
Từ khóa
Tài liệu tham khảo
American Psychiatric Association (2004) Practice Guidelines for the Treatment of Patients with Schizophrenia. American Psychiatric, Washington DC
Baldessarini RJ (1985) Clinical and epidemiologic aspects of tardive dyskinesia. J Clin Psychiatry 46:8–13
Ballesteros J, Gonzalez-Pinto A, Bulbena A (2000) Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. J Clin Psychopharmacol 20:188–194
Bertilsson L, Dahl ML, Dalén P, Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53:111–122
Bertilsson L (2007) Metabolism of Antidepressant and Neuroleptic Drugs by Cytochrome P450s: Clinical and Interethnic Aspects. Clin Pharmacol Ther 82:606–609
Browne S, Roe M, Lane A, Gervin M, Morris M, Kinsella A, Larkin C, Callaghan EO (1996) Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand 94:118–124
Caligiuri MP, Lacro JP, Rockwell E, McAdams LA, Jeste DV (1997) Incidence and risk factors for severe tardive dyskinesia in older patients. Br J Psychiatry 171:148–153
Casey DE (1997) Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia? Int Clin Psychopharmacol 12(Suppl 1):S19–S27
Chiu HF, Wing YK, Kwong PK, Leung CM, Lam LC (1993) Prevalence of tardive dyskinesia in samples of elderly people in Hong Kong. Acta Psychiatr Scand 87:266–268
Chiu H, Shum P, Lau J, Lam L, Lee S (1992) Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong. Am J Psychiatry 149:1081–1085
Chong SA, Mahendran R, Machin D, Chua HC, Parker G, Kane J (2002) Tardive dyskinesia among Chinese and Malay patients with schizophrenia. J Clin Psychopharmacol 22:26–30
Correll CU, Schenk EM (2008) Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 21:151–156
de Leon J (2007) The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study. Eur Arch Psychiatry Clin Neurosci 257:169–172
Fenton WS, Wyatt RJ, McGlashan TH (1994) Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry 51:643–650
Glazer WM (2000a) Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 61(Suppl 4):15–20
Glazer WM (2000b) Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 61(Suppl 4):21–26
Guy W (1976) ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-388. US Department of Health, Education, and Welfare
Gold JM, Egan MF, Kirch DG, Goldberg TE, Daniel DG, Bigelow LB, Wyatt RJ (1991) Tardive dyskinesia: neuropsychological, computerized tomographic, and psychiatric symptom findings. Biol Psychiatry 30:587–599
Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, Bailey A, Fell RL, McAdams LA (1995) Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 52:756–765
Jeste DV (2004) Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry 65(Suppl 9):21–22
Kane JM, Smith JM (1982) Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 39:473–481
Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J (1986) Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22:254–258
Kane JM (2004) Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 65(Suppl 9):6–20
Kasper S, Lowry AJ, Hodge A, Bitter I, Dossenbach M (2006) Tardive dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America. Schizophr Res 81:139–143
Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276
Ko GN, Zhang LD, Yan WW, Zhang MD, Buchner D, Xia ZY, Wyatt RJ, Jeste DV (1989) The Shanghai 800: prevalence of tardive dyskinesia in a Chinese psychiatric hospital. Am J Psychiatry 146:387–389
Leung A, Chue P (2000) Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl 401:3–38
Liddle PF, Barnes TR, Speller J, Kibel D (1993) Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia. Br J Psychiatry 163:776–780
Lohr JB, Kuczenski R, Niculescu AB (2003) Oxidative mechanisms and tardive dyskinesia. CNS Drugs 17:47–62
McCreadie RG, Thara R, Kamath S, Padmavathy R, Latha S, Mathrubootham N, Menon MS (1996) Abnormal movements in never-medicated Indian patients with schizophrenia. Br J Psychiatry 168:221–226
Morgenstern H, Glazer WM (1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. results of the yale Tardive Dyskinesia study. Arch Gen Psychiatry 50:723–733
Nilsson A, Waller L, Rosengren A, Adlerberth A, Wilhelmsen L (1997) Cigarette smoking is associated with abnormal involuntary movements in the general male population—a study of men born in 1933. Biol Psychiatry 41:717–723
Patterson BD, Swingler D, Willows S (2005) Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa. Schizophr Res 76:89–97
Pi EH, Gutierrez MA, Gray GE (1993) Cross-cultural studies in tardive dyskinesia. Am J Psychiatry 150:991
Remington G (2007) Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 20:131–137
Schooler NR, Kane JM (1982) Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39:486–487
Soares KV, McGrath JJ (1999) The treatment of tardive dyskinesia: a systematic review and metaanalysis. Schizophr Res 39:1–16
Tamminga CA (1997) Gender and schizophrenia. J Clin Psychiatry 58(Suppl 15):33–37
Tan CH, Tay LK (1991) Tardive dyskinesia in elderly psychiatric patients in Singapore. Aust N Z J Psychiatry 25:119–122
Thelma B, Srivastava V, Tiwari AK (2008) Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics 9:1285–306
van Harten PN, Hoek HW, Matroos GE, van Os J (2006) Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao extrapyramidal syndromes study V. J Clin Psychiatry 67:1920–1927
van Os J, Fahy T, Jones P, Harvey I, Toone B, Murray R (1997) Tardive dyskinesia: who is at risk? Acta Psychiatr Scand 96:206–216
van Os J, Walsh E, van Horn E, Tattan T, Bale R, Thompson SG (2000) Changes in negative symptoms and the risk of tardive dyskinesia: a longitudinal study. UK700 Group. Acta Psychiatr Scand 101:300–306
Woerner MG, Kane JM, Lieberman JA, Alvir J, Bergmann KJ, Borenstein M, Schooler NR, Mukherjee S, Rotrosen J, Rubinstein M (1991) The prevalence of tardive dyskinesia. J Clin Psychopharmacol 11:34–42
Woods SW (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64:663–667
Wszola BA, Newell KM, Sprague RL (2001) Risk factors for tardive dyskinesia in a large population of youths and adults. Exp Clin Psychopharmacol 9:285–296
Yassa R, Jeste DV (1992) Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 18:701–715
Youssef HA, Waddington JL (1987) Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr Scand 75:74–77